Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic BCG for prevention of NMIBC postoperative recurrence
ChiCTR2600118454Phase 3Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: One-year recurrence-free survival rate (1-year RFS%). Started Feb 2026; status: recruiting.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2600118454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118454.